Trials / Completed
CompletedNCT02038569
An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects
Effect of Calcipotriol Plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 Months) With Scalp and Body Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 125 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
An international, multi-centre, prospective, non-controlled, open, single-group, 8-week trial in adolescent subjects (aged 12 to 16 years, 11 months) with scalp and body psoriasis.
Detailed description
A phase 2 trial evaluating the safety and efficacy of once daily use of LEO 80185 gel containing calcipotriol 50 mcg/g plus betamethasone 0.5mg/g (as dipropionate) in adolescent subjects (aged 12 to 16 years, 11 months) with scalp and body psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LEO 80185 gel |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2018-02-01
- Completion
- 2018-02-13
- First posted
- 2014-01-16
- Last updated
- 2025-03-10
- Results posted
- 2018-11-06
Locations
35 sites across 7 countries: United States, Canada, France, Germany, Poland, Romania, United Kingdom
Source: ClinicalTrials.gov record NCT02038569. Inclusion in this directory is not an endorsement.